From Tel-Aviv to Detroit: How UltraSight Is Rewriting the Rules of Cardiac Imaging
Written by Casey Iaccino, MIBA Director of Innovation and Economic Expansion
The Road So Far
UltraSight’s journey already reads like a checklist for breakout health-tech success:
- $23.05 million raised from NYU Ventures, Yeda, Mayo Clinic, Yozma Group, Iron Nation, and a cadre of U.S. family offices controlling more than $300 million in assets.
- Regulatory sweep: FDA 510(k) and CE/UKCA in 2023, followed by Korean KFDA clearance this June.
- Clinical proof: In a Detroit feasibility study led by Dr. Philip Levy at Wayne State, first-time users captured diagnostic-quality cardiac views 93 percent of the time.
- Elite accelerators: Hand-picked by the American Society of Echocardiography to help write the very training guidelines that will govern AI-guided imaging.
And momentum is accelerating. A fresh oHCM study with Cleveland Clinic—run jointly with Bristol Myers Squibb—went live this month, while new data presented alongside Mayo Clinic at ACC 2025 underlined the platform’s accuracy and reach.
Why Detroit Is on the Ultrasound Map
UltraSight’s executives will touch down in Michigan early July—and their calendars are full for good reason.
- Digital-health capital. Michigan investors have backed nine Series A/B AI-health deals since 2023; in addition several prominent global firms (BayMed, CBIV, Iron Nation) are slated for UltraSight’s upcoming Series B alongside anchor commitments from Mayo and Cleveland Clinic Ventures.
- Deep clinical benches. Cardiologists at Henry Ford Health and Corewell Health run echo labs that process thousands of scans a year—perfect sandboxes for stress-testing real-time guidance.
- Hardware talent. Contract manufacturers from Midland to Detroit understand medical plastics, firmware, and FDA QMS—exactly what a J&J/Abiomed “build-to-buy” path demands.
- Turn-key soft-landing. UltraSight already swiped an access badge to MIBA’s Elevator, giving the team desks, mentors, and a front-row seat to Michigan’s med-tech ecosystem.
What Comes Next—and Where You Fit
Series B: UltraSight is opening a new round to scale U.S. sales, advance R&D, and convert pilot studies into system-wide deployments.
You are…
Here’s your angle
Hospitals / clinics
Pilot the software and train frontline staff before nationwide rollout.
Med-device suppliers
Explore white-label or bundled offerings—handheld probes, carts, even integrated EHR modules.
Investors
Review the pitch deck; book a one-on-one during the July visit to discuss syndication.
A final note: UltraSight’s founders like to say their AI gives every clinician “the eyes of an expert.” If Michigan has its way, those eyes will soon be found in every ambulance, clinic, and community hospital from Detroit to the Upper Peninsula—proof that world-class innovation and Midwestern heart can beat perfectly in sync.
